Rosuvas 10 mg = rosuvastatin 10 mg, a moderate-intensity statin that usually lowers LDL cholesterol by about 30% to 49%.
It is started to reduce LDL cholesterol and future atherosclerotic cardiovascular disease risk, commonly when a person has:
- Established cardiovascular disease: prior heart attack, angina, coronary stent/bypass, ischemic stroke/TIA, or peripheral arterial disease.
- LDL-C markedly elevated, particularly ≥190 mg/dL (4.9 mmol/L), often suggesting familial hypercholesterolemia. This often needs high-intensity treatment rather than 10 mg alone.
- Diabetes, usually age 40-75, especially with additional cardiovascular risk factors.
- Primary prevention: no known vascular disease, but calculated cardiovascular risk is sufficiently elevated after discussion of blood pressure, smoking, LDL-C, family history, kidney disease, Lp(a), etc.
- Hypercholesterolemia or mixed dyslipidemia when lifestyle measures alone have not achieved the agreed lipid goal.
Recent ACC guidance identifies statins as first-line LDL-lowering treatment and includes diabetes, chronic kidney disease, LDL-C ≥190 mg/dL, and assessed cardiovascular risk among the main settings for initiating therapy.
ACC dyslipidemia guidance
Before starting, obtain or review: fasting or non-fasting lipid profile, ALT/liver history, blood pressure, diabetes status, smoking status, kidney function, current medicines, and pregnancy status. Rosuvastatin should not be used during pregnancy or breastfeeding. Seek medical review promptly for unexplained severe muscle pain/weakness or dark urine after starting.
A decision for an individual cannot be made from the dose alone. The key details are age, LDL/HDL/triglycerides, diabetes/CKD status, blood pressure, smoking, and any prior heart or stroke event.